Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) were the recipient of a significant growth in short interest in the month of January. As of February 14th, there was short interest totalling 1,594,585 shares, a growth of 83.0% from the January 31st total of 871,197 shares, Stock Ratings News reports. Based on an average daily volume of 821,389 shares, the days-to-cover ratio is currently 1.9 days. Currently, 7.4% of the shares of the company are sold short. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) stock opened at $21.44 in last session, and closed at $20.95, while the day range of AMAG stock is $20.89-$22.00. The stock showed a positive weekly performance of 2.94%.
Shareholders of Meridian Bioscience, Inc. (NASDAQ:VIVO) looking to boost their income beyond the stock’s 3.7% annualized dividend yield can sell the July covered call at the $22.50 strike and collect the premium based on the 80 cents bid, which annualizes to an additional 10.2% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 13.9% annualized rate in the scenario where the stock is not called away. Any upside above $22.50 would be lost if the stock rises there and is called away, but VIVO shares would have to climb 4.8% from current levels for that to happen, meaning that in the scenario where the stock is called, the shareholder has earned a 8.6% return from this trading level, in addition to any dividends collected before the stock was called. Meridian Bioscience, Inc. (NASDAQ:VIVO) stock opened at $21.76, in last session and closed at $21.80, by loosed -0.18%. The 52 week range was $19.15-$27.72.Company’s market capitalization is $905.82 million.
Piper Jaffray started coverage on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research note released on Monday morning, The FlyOnTheWall.com reports. The firm issued a neutral rating and a $125.00 target price on the stock. IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock gained 0.53% and finished the last session at $128.26.The EPS of the stock remained 3.52.Company’s market capitalization is $6.62 billion.
Atossa Genetics Inc. (NASDAQ:ATOS) has reported that the US Food and Drug Administration, the federal regulatory body, has sought more information and data to further review an application for a breast aspirator called ForeCYTE, developed by ATOS. Atossa Genetics Inc (NASDAQ:ATOS) stock opened the session at $1.85, and closed the session at $1.82. The 52 week range of the ATOS stock remained $1.74-$12.40 and the day range was $1.80-$1.85.
Leave a Reply